Anybody else out there interested in these?

2002 Results are due in April, and they are expected to show a maiden profit.
Last week I opened a small speculative long (spreadbet), but I am looking to add to this position a lot more if we get any sort of resolution over Iraq crisis before the results which should spark a broad market rally from which SKP could really benefit and have a strong run-up.

DYOR etc.


Here is a recent research note from Merrill Lynch (they estimate 0.25p EPS for 2002):


Merrill Lynch FlashNote

7 February 2003

SkyePharma

Newsflow Set To Continue BUY

Reason for Report: Company Update

EPS (Dec): 2001A -1.19p; 2002E 0.25p; 2003E 2.13p
P/E (Dec): 2001A NM; 2002E 180.0x; 2003E 21.1x

Michael Ashton, CEO SkyePharma, gave an upbeat and informative presentation today.

Depomorphine appears on track for US submission in June 03. The two pivotal trials (hip and lower abdominal surgery) have been concluded. To date, the results appear encouraging. Management believe that safety (eg respiratory depression and nausea) is not an issue for the drug.The company is also conducting an additional trial in C section patients which is completing enrollment and should be included in the European submission for Depomorphine later this year. We expect the pivotal trial data for Depomorphine to be presented at the American Society of Clinical Anaesthesiologists in October 2003.

Paxil CR continues to grow (accounting for c.26% of total Paxil scrips in the US). 50% of these Paxil CR scrips are repeat and Paxil CR accounts for c.7% of the total SSRI antidepressant market in the US. Paxil CR is already filed for pre-menstrual dysphoria disorder (PMDD). However, GSK also plans to submit the intermittent treatment of PMDD later this year.

SKP also confirmed that Quintiles plans to present new data for Solaraze at the American Society of Dermatology in March. SKP believes that Solaraze is making in-roads into the actinic keratosis market and appears to be taking market share from Ephedrex (5-FU). Clinical trials in Australia are on track, with SKP planning to submit Solaraze to the Australian regulatory authorities in 2004 (second largest market opportunity after the US).

Enzon has already started to market DepoCyt in the US and SKP expects to see wider usage of the drug by key oncologists in the next few months. Phase IV studies for the neoplastic meningitis indication are on track, with an FDA Advisory Committee meeting (ODAC) scheduled next month.

Overall, we expect the newsflow for SKP to continue and reiterate our BUY recommendation with a price objective of 80p (based on applying the speciality pharma multiple to our 06E EPS of 14p and discounting back agressively at 30% p.a.). Risks to the stock include the general risk of drug development delay and product approval failure.

Again, well said Fundamentalist. wa157te - put up (i.e. share this impending news of doom to the benefit of all if you're that concerned about our welfare) or f*ck off.

From the KMR thread:

pro - 29 May'05 - 08:10 - 378 of 378


Why are you so afraid of bad news???
Pull that wool from over your eyes which Kivver and others have put there. This share is a dog with fleas and has never been worth any attention. You should sell now before the bad news hits the fan - or your pocket will feel the pinch!!!

From post 122 on this thread:

wa157te - 29 May'05 - 08:21 - 122 of 124


Why are you so afraid of bad news???
Pull that wool from over your eyes which Kivver and others have put there. This share is a dog with fleas and has never been worth any attention. You should sell now before the bad news hits the fan - or your pocket will feel the pinch!!!

Says it all really.

gav

also try CYH and PIC threads for the same post as well as similar boards on advfn

Can something not be done about this idiot by MoneyAM?

It's no good bleating on about repetitive posting. Do you expect to be able to brush the bad news under your carpet?? Let people know what a bad company this is!!!
Or I will!!!

Queen1

have emailed MAM - balls in their court

Pro - what bad news - as before your statement is completely unjustified

Bye Bye Pro, you've already had a warning and have now outstayed your welcome.

Fundy,

Just read Mr Multinames posts that you point out here and over the road. Funny how the posts are all identical apart from the posters name! I'm sure you would agree with me that if someone has a genuine bear point to make then by all means go ahead and make it. This guy has made no such case that I can see anyway, his posts are garbage. On threads where I post, I would welcome both sides of the case, even if I disagreed with an arguement. I hope MAM will look into this as surely posting under several alias's should not be allowed, whether they are bullish or bearish posts.

gavdfc

AM I believe have already issued a warning to this joker, hopefully Ian will take the correct action on Tuesday morning and remove him and his multiple personalities from the Board. All of his repetitive posts on the AXM thread were removed last week, although he has started the same old crap again.

pth

pth,

Thanks for that. Hopefully Ian can sort this out as posts such as his under various alias's add nothing at all to the site or individual threads. I'm sure we would all agree that the last thing we want is for this site to be dragged down to the quaility of a certain other site.

Cheers

Gav

There is no doubt about it -Kivver has well and truly lost the plot!!
Well how can you believe in someone who (see 'Worst Ramper Deramper Competition (RAMP)' post) admits to having multiple posting names (why the need for deception??) and who descends to ranting and raving at other posters???
I prefer to listen to balanced people who remain balanced in all situations where my investments are concerned.
And that's a fact!

Ah, the prat's back. Come on MoneyAM, get rid of this idiot.

I noticed the prat on the PIC thread....made me smile..I hope his timing is as good with all his trading.

i hope skp doesin a day the same as pic....

This should alleviate the uncertainty surrounding the July maturing convertible bonds:

RPT Skyepharma to privately place 20 mln stg of convertible bonds
AFX

LONDON (AFX) - Skyepharma PLC has signed agreements for a private
placement of 20 mln stg of new convertible bonds.

The pharmaceutical company said the funds will be used to defray corporate expenses, including the 9.8 mln stg likely to be required for the forthcoming redemption of its 6 pct convertible bond due 2005.

It will also satisfy projected use of cash for the foreseeable future, SkyePharma said.

The new convertible bonds, which have a coupon of 8.0 pct and a first put after 5 years with a final maturity of 2025, have a conversion price premium of 50 pct to the volume-weighted average share price of SkyePharma on May 27.

Michael Ashton, SkyePharma's Chief Executive, said: 'On April 28 (we) made reference to the fact that the company's working capital requirements are sensitive to the timing and receipt of milestone payments and payments received on the signing of new contracts.

'Since that date, the FDA has approved Triglide, triggering a 15 mln usd milestone payment... and we are working toward the conclusion of a definitive agreement for the licensing of our major pulmonary product Flutiform.

'In the mean time, (we) felt it was in the best interest of the company to remove any uncertainty in respect of the company's financial resources.'

tc

http://www.m2.com/m2/web/story.php/2005785B99A67EFD32C5802570590059C9A0

batteryman

any chance you can post the full article as it requires subscription access

ING has a buy rating and 80p price target for Skyepharma (Friday 12th August).

its about the share price reflected the hype! been waiting a long time.

So what's going to drive the price from 58p to 80p then in their opinion?